There are 2949 resources available
646P - Prostate cancer metastatic profiles correlate with molecular alterations
Presenter: Olivier Cussenot
Session: E-Poster Display
Resources:
Abstract
647P - Clinical implications of intraductal carcinoma of the prostate sub-patterns in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel as the first-line therapy
Presenter: Wang Zhipeng
Session: E-Poster Display
Resources:
Abstract
648P - Abiraterone and dexamethasone in castration-resistant prostate cancer: Biological response after switch or rechallenge
Presenter: Mathieu Jamelot
Session: E-Poster Display
Resources:
Abstract
649P - Abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy: A double-arm, multiple-centre, phase III clinical study
Presenter: Zhiquan Hu
Session: E-Poster Display
Resources:
Abstract
650P - Comparing the predictive value of exosome, circulating tumor cells, and tumor tissue in detecting AR-V7 among metastatic castration-resistant prostate cancer treated with abiraterone
Presenter: Sha Zhu
Session: E-Poster Display
Resources:
Abstract
651P - Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study
Presenter: Giulia Baciarello
Session: E-Poster Display
Resources:
Abstract
652P - Comparison of current systemic combination therapies for metastatic hormone-sensitive prostate cancer and selection of candidates for optimal treatment: A systematic review and Bayesian network meta-analysis
Presenter: Junru Chen
Session: E-Poster Display
Resources:
Abstract
653P - Features of molecular profile of prostate cancer after neoadjuvant treatment
Presenter: Mary Berkut
Session: E-Poster Display
Resources:
Abstract
654P - Real-world treatment (Tx) patterns in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm+)
Presenter: Neal Shore
Session: E-Poster Display
Resources:
Abstract
655P - Prognostic significance of docetaxel (D) plus androgen-deprivation therapy (ADT) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) according to extent of disease: A study of real-world data
Presenter: Lucía Notario
Session: E-Poster Display
Resources:
Abstract